Loading
Establishment Labs Holdings Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by LEWIN NICHOLAS SHERIDAN, was filed 14 Aug 2025.
Insider Decl.
302
Thresholds
n/a
Buy Volume
€9M
36 ops. · all time
Sell Volume
€31M
96 ops. · all time
Who traded when
BuySaleQuiros Juan Jose Chacon15 sales
JW Asset Management, LLC10 sales
Nicholas Sheridan Lewin2 buys
Filippo Caldini1 buy
Since the insiders bought
- +99.9%Entry US$38.32 · Close at T+365 US$76.62
- +124.8%Entry US$33.62 · Close at T+365 US$75.58
- +72.7%Entry US$24.21 · Close at T+365 US$41.81
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Establishment Labs Holdings Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$100.70.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,658 of 26,280 companies
28.7
score / 100
Value26
Quality32
FCF yld-3.1%
Earn yld-2.8%
EV/EBITDA·
ROE-175%
Gross mgn69%
Net mgn-24%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$62.28
Analyst consensus
10 analystsStrong buy
US$85.00Target US$100.70(+62%)US$117.00
Income statement
RevenueUS$211.1M
Gross profitUS$146.3M69% margin
EBITDA-US$22.3M-11% margin
Net income-US$51.1M-15.8% margin
Valuation
PER (forward)1038.0x
P/Book85.9x
Beta1.06
Balance sheet & cash
Market capUS$1.9B
Total debtUS$264.5M
Free Cash Flow-US$57.6M
Debt / Equity1220%
Profitability & ownership
ROE-175.3%
ROA-3.4%
% insiders10.0%
% institutions105.5%
Last declaration on 2 October 2026
Declarations302 total
389 shares@ US$64.170.0013% mcap100.0% of flowCommon SharesSEC:0001398327-26-000011:0
301 shares@ US$64.170.0010% mcap100.0% of flowCommon SharesSEC:0001863404-26-000007:0
262 shares@ US$64.170.0009% mcap100.0% of flowCommon SharesSEC:0001862601-26-000007:0
253 shares@ US$64.170.0008% mcap100.0% of flowCommon SharesSEC:0001861660-26-000008:0
253 shares@ US$64.170.0008% mcap100.0% of flowCommon SharesSEC:0001254555-26-000008:0
682 shares@ US$71.520.0024% mcap100.0% of flowCommon SharesSEC:0001839059-26-000006:0
11,315 shares0Common SharesSEC:0001742429-26-000022:0
189 sharesCommon SharesSEC:0001861660-26-000005:0
196 sharesCommon SharesSEC:0001862601-26-000005:0
291 sharesCommon SharesSEC:0001398327-26-000005:0
216 sharesCommon SharesSEC:0001254555-26-000006:0
239 sharesCommon SharesSEC:0001863404-26-000005:0
1,949 sharesCommon SharesSEC:0001628280-26-046089:0
1,281 sharesCommon SharesSEC:0001628280-26-046089:1
24,198 shares@ US$83.79100.0% of flowCommonSEC144:0001950047-26-006110
113 shares@ US$72.500.0003% mcap0.0% of flowCommon SharesSEC:0001104659-26-067739:1
25,320 shares@ US$74.390.076% mcap9.4% of flowCommon SharesSEC:0001104659-26-067739:0
65,100 shares@ US$72.890.19% mcap23.8% of flowCommon SharesSEC:0001104659-26-067739:2
3,580 shares@ US$70.560.010% mcap1.3% of flowCommon SharesSEC:0001104659-26-065826:0
16,999 shares@ US$71.400.049% mcap6.1% of flowCommon SharesSEC:0001104659-26-065826:1
22,610 shares@ US$65.6570.054% mcap18.0% of flowCommon SharesSEC:0001742429-26-000015:4
7,568 shares@ US$66.1290.018% mcap6.1% of flowCommon SharesSEC:0001742429-26-000015:5
165 shares@ US$67.1440.0004% mcap0.1% of flowCommon SharesSEC:0001742429-26-000015:8
4,936 shares@ US$64.8340.012% mcap3.9% of flowCommon SharesSEC:0001742429-26-000015:0
30,549 shares@ US$65.330.073% mcap24.2% of flowCommon SharesSEC:0001742429-26-000015:1
25 of 302 declarations
About Establishment Labs Holdings Inc.
JW Asset Management, LLC, which files as a holder of more than 10%, sits at both ends of the Establishment Labs Holdings Inc. record: the largest purchase (EUR 2,248,735 on April 13, 2022) and the two largest sales (EUR 4,295,571 on December 4, 2024 and EUR 4,085,565 on May 28, 2026). The third sale is by director Quiros Juan Jose Chacon, for EUR 2,073,027 on April 14, 2026.
This US healthcare company, listed on Nasdaq and valued at USD 1.7 billion, has 302 filings from 23 filers between July 23, 2018 and October 2, 2026. They include 96 sales worth EUR 31.1 million (median EUR 112,596), 36 purchases worth EUR 9.2 million (median EUR 45,446), 133 grants and 11 option exercises. Purchases make up 27% of market trades.
Read moreShow less
The pace has picked up: 45 filings in 2024, 45 in 2025 and 54 in 2026, against 9 in 2018. Over the last twelve months, 58 filings were published, of which 23 sales and no purchase. They come out a median of 2 days after the trade. For 34 purchases a 90-day result is stored: median 10.6%, 62% positive (stored past results, not a forecast).
